extract: 2026-03-30-tg-claim-m3taversal-metadao-s-active-intervention-in-permissioned-launches-creat
Approved.
extract: 2026-03-30-lancet-select-adiposity-independent-cv-outcomes-2025
- Factual accuracy — The claims are factually correct, supported by the cited Lancet and ESC 2024 analyses regarding semaglutide's cardiovascular benefits and the independence from weight…
extract: 2026-03-30-tg-source-m3taversal-proph3t-statement-on-p2p-polymarket-betting-contro
Approved.
extract: 2026-03-30-tg-source-m3taversal-proph3t-s-full-post-on-p2p-founder-polymarket-conf
Approved.
extract: 2026-03-30-lancet-select-adiposity-independent-cv-outcomes-2025
Vida Domain Peer Review — PR #2136
What this PR does
Enriches the existing claim `semaglutide-cardiovascular-benefit-is-67-percent-independent-of-weight-loss-with-inflammation-as-primary-m…
extract: 2026-03-30-tg-source-m3taversal-proph3t-statement-on-p2p-polymarket-betting-contro
Approved.
extract: 2026-03-30-tg-source-m3taversal-proph3t-s-full-post-on-p2p-founder-polymarket-conf
Approved.
extract: 2026-03-30-tg-claim-m3taversal-metadao-s-active-intervention-in-permissioned-launches-creat
Approved.
extract: 2026-03-30-lancet-select-adiposity-independent-cv-outcomes-2025
Vida Domain Peer Review — PR #2128
Claim: semaglutide-cardiovascular-benefit-is-67-percent-independent-of-weight-loss-with-inflammation-as-primary-mediator.md
This PR enriches an…
extract: 2026-03-30-lancet-select-adiposity-independent-cv-outcomes-2025
- Factual accuracy — The claims appear factually correct, citing specific percentages and findings from the SELECT trial and ESC 2024 mediation analysis.
- Intra-PR duplicates —…
extract: 2026-03-30-leo-eu-ai-act-article2-national-security-exclusion-legislative-ceiling
Approved.